RE: Sharetalk6 Jan 2025 06:30
Looking Ahead to 2025
Avacta’s progress with AVA6000 and the pre|CISION™ platform positions it as a standout in precision medicine. As the Phase 1b expansion cohorts progress and data emerges, the company’s ability to transform cancer treatment will come into sharper focus. For investors, Avacta represents an exciting opportunity to support cutting-edge innovation in oncology, with 2025 shaping up to be a critical year for its evolution.